Effectiveness and Safety of #Apixaban Compared With #Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study

Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety and effectiveness are lacking.. 39 351 patients newly prescribed apixaban were propensity score matched to 39 351 patients newly prescribed rivaroxaban. Mean age was 69 years, 40% of patients were women, and mean follow-up was 288 days for new apixaban users and 291 … Continue reading Effectiveness and Safety of #Apixaban Compared With #Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study

FDA Approves New Treatment for Adults with #Cushing’s Disease

The U.S. Food and Drug Administration today approved Isturisa (#osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Cushing’s disease is a rare disease in which the adrenal glands make too much of the cortisol hormone. Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by … Continue reading FDA Approves New Treatment for Adults with #Cushing’s Disease